Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

Stopped Drug supply issues

Conditions

• Metastatic Malignant Solid Neoplasm
• Recurrent Lung Small Cell Carcinoma
• Recurrent Malignant Solid Neoplasm
• Refractory Malignant Solid Neoplasm
• Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7
• Stage IIIA Lung Small Cell Carcinoma AJCC v7
• Stage IIIB Lung Small Cell Carcinoma AJCC v7
• Stage IV Lung Small Cell Carcinoma AJCC v7
• Unresectable Solid Neoplasm

Interventions

• BIOLOGICAL: Navitoclax
• DRUG: Vistusertib

Sponsor

National Cancer Institute (NCI)